Avacincaptad pegol

(Izervay®)

Izervay®

Drug updated on 11/17/2023

Dosage FormInjection (intravitreal; 20 mg/mL in a single-dose vial)
Drug ClassComplement inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Product Monograph / Prescribing Information

Document TitleYearSource
Izervay (avacincaptad pegol) Prescribing Information.2023IVERIC Bio, Inc., Cranbury, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Complement inhibitors for age-related macular degeneration.2023Cochrane Database of Systematic Reviews